AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
Phase 1
Terminated
- Conditions
- Cancer,Solid TumorsAdvanced Solid Malignancies
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00733031
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Depiction of Prostate Cancer Treatment Alternatives in Greece
Completed
- Conditions
- Locally Advanced or Metastatic Prostate Cancer.
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT00733213
- Locations
- 🇬🇷
Research Site, Xsanthi, Greece
A Study of Tor Kinase Inhibitor in Advanced Tumors
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00731263
- Locations
- 🇬🇧
Research Site, Sutton, Surrey, United Kingdom
Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2008-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00729443
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT00729326
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
Phase 1
Completed
- Conditions
- Adverse EventsPharmacokinetic Variables
- Interventions
- Drug: ABT-143
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00728780
- Locations
- 🇺🇸
Site Reference ID/Investigator# 11101, Evansville, Indiana, United States
Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00727883
Renal Mechanism of Action/Splay vs. TmG
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1
- Registration Number
- NCT00726505
- Locations
- 🇺🇸
University Of Texas Health Center At San Antonio, San Antonio, Texas, United States
A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00726427
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
Completed
- Conditions
- Hyperlipidemias
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3270
- Registration Number
- NCT00726362
- Locations
- 🇨🇳
Research Site, Yun-Lin, Taiwan
© Copyright 2025. All Rights Reserved by MedPath